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Abstract
Background: Hyperhomocysteinemia has been described as a risk factor for unexplained recurrent pregnancy loss.
Increased levels of homocysteine may be due to inadequate dietary intake of folate and vitamin B12 and inherited defects
within the methionine-homocysteine pathway such as MTHFR C677T gene polymorphism. However, the association
between hyperhomocysteinemia and sterility problems have been underlined only for recurrent pregnancy loss while a
relationship between hyperhomocysteinemia and female sterility is still matter of discussion.
Aim: This study sought to find out a possible relationship between sterility (primary sterility or secondary sterility due
to recurrent pregnancy loss) and homocysteine metabolism.
Patients and Methods: We selected 20 patients with recurrent pregnancy loss, 20 patients with unexplained female
sterility and 20 healthy women as control group. Several whole blood samples were collected by venipuncture. Firstly
homocysteinemia and other related variables were tested (i.e. folate and vitamin B12 levels); thereafter DNA was
extracted by a further whole blood sample collected in EDTA in order to screen MTHFR C677T gene polymorphism.
Statistical analysis was performed by chi square test; differences were considered to be significant if p < 0.05.
Results: The median fasting total plasma homocysteine concentration was 19.2 ± 6.14 μM for patients with recurrent
pregnancy loss, while was 21.05 ± 8.78 μM for patients with unexplained sterility, vs 7.85 ± 3.31 μM of control group (p
< 0.05). Fifteen patients with unexplained female sterility showed MTHFR C677T homozigosity vs 17 with recurrent
pregnancy loss and 3 in the control group (p < 0.05). On the other hand no significant differences were found in the levels
of vitamin B 12 in the three groups, while reduced folate concentrations were found in women with unexplained female
sterility and recurrent pregnancy loss (p < 0.05 vs control group.
Discussion: MTHFR C677T gene polymorphism is frequent in the studied populations. These data raise questions on
the role of the homocysteine metabolism in sterility problems. Even though increased homocysteine (i.e. > 15 μM) and
MTHFR C677T homozigosity have already been described as risk factors for recurrent pregnancy loss, few studies
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evaluated their role in women with unexplained sterility. Further studies on larger series are needed to better
understand the role of homocysteine metabolism, including folate metabolism, in this clinical setting.
Background
Hyperhomocysteinemia (HHCY) has been underlined as
an emerging risk factor for several diseases such as arterial
and/or venous thrombosis [1], adverse pregnancy out-
come [2,3], congenital malformations [4] and vascular
dementia [5,6]. Inherited and acquired conditions have
been involved to explain pathophysiology of HHCY such
as gene polymorphisms [i.e. cystationin beta synthase
(CBS) or methylenetetrahydrofolate reductase (MTHFR)]
[7,8] and folate and/or vitamin B6/B12 deficiencies due to
disregulation of their normal metabolism and/or low die-
tary intake [9-11]. Because HHCY has frequently been
associated to clinical vascular thrombosis, homocysteine
metabolism is investigated, together with other throm-
bophilic conditions such as inherited and/or acquired
thrombophilia, in patients with early onset of vascular
thrombosis [1]. However, in this field inherited and/or
acquired thrombophilia are identified as well known risk
factors for adverse pregnancy outcome, in particular in
case of early recurrent pregnancy loss (RPL). Literature
already underlined a strong relationship between inher-
ited deficiency of protein C, protein S or antithrombin
and RPL [12]. Moreover, gene variants related to throm-
bophilia as factor V Leiden and\or prothrombin A20210G
have been reported to be associated to RPL [13-15]. More-
over, acquired conditions such as antiphopspholipid syn-
drome or increased plasma levels of clotting factor VIII
have been associated to RPL [16-19]. Furthermore,
increasing evidence is now available also for the associa-
tion of HHCY and RPL [2,3].
Previous studies failed to include or exclude other causes
of miscarriages, when alteration of haemostasis with a
trend toward hypercoagulable state were considered. On
the other hand, few emerging data are now available for
the role of inherited and/or acquired thrombophilia in
women with in vitro fertilisation failure [20,21], while
data about the association of female sterility and altera-
tion of haemostasis are lacking, in particular if the homo-
cysteine metabolism is considered.
The aim of our study was therefore to investigate the role
of homocysteine metabolism in patients with unex-
plained female sterility or secondary sterility due to RPL.
Patients and Methods
Patients selection
We observed 125 consecutive women referred to our Ste-
rility Center for infertility due to RPL or for female steril-
ity. We considered for this study in the group of women
with RPL all patients with 2 or more first trimester abor-
tion or with 1 or more late pregnancy loss, while we con-
sidered women without any clear evidence of pregnancy
in their anamnesis in the group of women with unex-
plained female sterility (UFS).
In order to evaluate the causes of RPL or female sterility we
looked for chromosomal alterations, endocrine dysfunc-
tions, chronic inflammatory diseases, infectious diseases,
uterine malformations, tubal patency, alteration of hae-
mostasis with a trend toward thrombophilia.
All patients underwent karyotype study in order to detect
several chromosomal aberrations such as balanced trans-
locations.
Anatomic evaluation of the uterine cavity was performed
by transvaginal ultrasound scan and hysterosalpingogra-
phy and/or hysteroscopy in order to detect mullerian mal-
formations or the presence of fibroids or polyps and\or
tubal patency.
Endocrinological assessment included screening for dia-
betes, hypothyroidism, hypopituitarism, hyperprolacti-
naemia, luteal insufficiency and polycystic ovarian
syndrome (PCOS). Basal FSH, LH and oestradiol, luteal
phase progesterone, TSH, prolactin levels and fasting glu-
cose were evaluated in all patients. In addition, trans-vag-
inal USG and androgens levels were assessed to look for
PCOS and\or anovulation.
Chronic inflammations due immunological diseases such
as systemic erythematosus lupus, rheumatoid arthritis,
systemic sclerosis were also studied. Serum level of anti-
nuclear antibodies (ANA), antimithocondrial antibodies
(AMA), smooth muscle antibodies (SMA), rheumatoid
factor and levels of C reactive protein were assessed. Infec-
tive disease due to Chlamydia spp, were evaluated by spe-
cific Chlamydia assays (i.e. serological levels of specific IgG
and IgM against Chlamydia spp). Moreover, all patients
were examined for vaginal and cervical smears, in order to
exclude vaginal and\or cervical infections such as Chla-
midia spp or Mycoplasma spp or mycosis.
Alterations of haemostasis with a trend toward throm-
bophilia were excluded by specific assays to test protein C,
protein S and antithrombin deficiency, anticardiolipin
IgG and IgM antibodies, lupus anticoagulant, inherited
gene polymorphisms of factor V Leiden and A20210GThrombosis Journal 2007, 5:10 http://www.thrombosisjournal.com/content/5/1/10
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prothrombin. So, patients carrying hypercoagulable state
due the reported variables were excluded from the study.
Moreover, obese patients were excluded, in particular
women with Body Mass Index > 25 were not enrolled in
the study.
Patients group
After this screening we selected 20 patients with unex-
plained RPL and 20 women with UFS.
Selected women were tested for several variables of homo-
cysteine metabolism through methylene-tetra-hydro-
folate reductase (MTHFR) C677T gene polymorphism,
homocysteinemia, folate and vitamin B 12 levels. All
selected patients, both affected by UFS and RPL, were tak-
ing preconceptional doses of folic acid (i.e. 400 μg) in
order to prevent neural tube defects in case of pregnancy.
On the other hand none of control subjects was taking
folic acid.
Methods
Whole blood samples were collected from all selected
subjects in the study by venipuncture from antecubital
vein in order to screen possible involvement of alteration
of homocysteine metabolism. All subjects were assayed
for plasma homocysteine (t-Hcy), vitamin B12 and folic
acid levels and MTHFR C677T gene polymorphism.
First blood sample
The first blood sample was collected in EDTA to screen
fasting homocysteine (FPIA-Abbott).
Second blood sample
The second blood sample was collected in SST II advanced
tube in order to detect serum folic acid levels and serum
vitamin B 12 levels (CMIA-Abbott)
Third blood sample
A further blood sample (5 mL) was collected in EDTA in
order to screen gene variants of MTHFR C677T. DNA was
extracted using the "NUCLEON BACC" kit (Amershan,
Germany). Patients were screened for the C677T gene pol-
ymorphism of MTHFR using PCR amplification with spe-
cific primers and the Light Cycler apparatus (Roche, Italy).
Control group
Twenty age and sex matched healthy subjects were
enrolled as control group. Selected subjects had the same
ethnical background of the study group. In the control
group we included women with one or more successful
pregnancy and without gestational complication (intrau-
terine growth restriction, stillbirth and abruptio placen-
tae) and any abortion. We excluded subjects with previous
arterial and/or venous thrombosis. We also excluded sub-
jects with first degree relatives with arterial and/or venous
thrombosis before than 65 years old.
Statistical analysis
Statistical analysis was based on chi square test, differ-
ences were considered to be significant if p < 0.05. Statis-
tical analysis was carried out using SPSS statistical
software [22,23].
Results
Fasting levels of homocysteinemia were higher both in
patients with UFS (i.e. 21.05 ± 8.78 μM) and with RPL
(19.20 ± 6.14 μM) compared to control subjects (7.85 ±
3.31 μM); differences were both statistically significant (p:
<0.01) (Table 1 and 2). Fasting homocysteine was slightly
increased in patients with unexplained sterility compared
to patients with RPL, but this difference did not reach sta-
tistical significance (Table 1 and 2).
Moreover, serum folic acid levels were lower both in
women with UFS (6.70 ± 4.50 ng/ml) and by RPL (6.10 ±
2.81 ng/ml) compared to control subjects (20.10 ± 9.44
ng/ml) and also these differences reached statistical signif-
icance (p: <0.01) (Table 1 and 2). Interestingly, in this
case we found also a significant statistical difference in
folate concentrations in women with unexplained sterility
compared to women with RPL (p: 0.007) (Table 1 and 2).
Serum vitamin B12 levels were comparable in women
with UFS (648 ± 162 pg/dl), in women with RPL (608 ±
154 pg/dl) and in control subjects (664 ± 175 pg/dl)
(Table 1 and 2) not reaching significant statistical differ-
ences (Table 2).
MTHFR C677T gene polymorphism was searched for in
all subjects with UFS, RPL and in controls. Five/20
patients with UFS and 3/20 patients with RPL showed het-
erozigosity for MTHFR C677T compared to 9/20 of con-
trol group (Table 2).
MTHFR C677T homozigosity was present in 15/20
patients with UFS and 17/20 patients with RPL compared
to 3/20 subjects of control group (Table 1); differences
were significant both for sterility and RPL when compared
to control group (p: <0.01 UFS vs control group and RPL
vs control group) (Table 2). No differences were found
between UFS and RPL (p: 0.69, ns) (Table 2). None of the
subjects with UFS or RPL were wild type for MTFHR
C677T gene polymorphism vs 8\20 subjects of control
group.
Results showing variables in patients with unexplained
female sterility, RPL and control group are summarised in
Table 1 and 2.Thrombosis Journal 2007, 5:10 http://www.thrombosisjournal.com/content/5/1/10
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Discussion
Since 1990 several studies underlined a pathogenic role
for inherited thrombophilia in women with RPL [24,25].
A pathogenic role was identified for inherited deficiency
of protein C, protein S and antithrombin and for inher-
ited gene polymorphism of factor V Leiden and A20210G
of prothrombin, and also for acquired thrombophilia, in
particular antiphospholipid syndrome [12-19].
Also a potential pathogenic role of HHCY has been
recently suggested, because the association of HHCY and
thrombosis, but not univocal data are available. Increas-
ing evidences are available for the relationship between
HHCY and MTHFR C677T gene polymorphism and unex-
plained recurrent pregnancy loss. Several reports, in fact,
described an association between early RPL and HHCY
and/or MTHFR C677T gene polymorphism [2,3,26,27]. A
different point of view on the association between HHCY
and RPL has been reported only by Makino et al. [28].
Only a few studies are available on the association
between sterility and HHCY and they are focused only on
women with in vitro fertilization failures. Moreover, avail-
able data seem to be in contrast: Martinelli et al. did not
find an association between inherited thrombophilia and
patients with in vitro fertilization failure [29], while Azem
et al. and Qublan et al. underlined a possible role of inher-
ited thrombophilia and IVF failure [20,21]. However,
both studies were not based on a possible association of
homocysteine metabolism and IVF failure but only on the
C677T gene polymorphism of MTHFR.
In the present study we evaluated not only homocysteine-
mia and MTHFR C677T gene polymorphism but also
other common variables associated with homocysteine
metabolism such as folate and vitamin B12 serum levels
both in women showing RPL and women with UFS.
We found that women with RPL and UFS showed HHCY
compared to control group (Table 1 and 2). We did not
find differences in homocysteine levels between women
with RPL and women with UFS. Although data concern-
ing HHCY and RPL seem to be in agreement with those
already reported [2,3,26,27], data focusing the association
between of HHCY and UFS are innovative because rarely
described so far.
Data concerning MTHFR C677T gene polymorphism
seem to support this hypothesis because we found a high
frequency of homozigosity of TT genotype not only in
Table 2: Statistical differences between patients with unexplained female sterility, patients with RPL and control subjects
Hcy (μM/ml) p Serum folate 
(ng/ml)
PS e r u m  v i t .  
B 12 (pg/
ml)
p MTHFR C677T 
heterozigosity
pM T H F R  
C677T 
homozigosity
p
UFS vs CG 21.05 ± 8.78 vs 
7.85 ± 3.31
<0.01, s 6.70 ± 4.50 vs 
20.10 ± 9.44
<0.01, s 648 ± 162 vs 
664 ± 175
0.35, ns 5/20 vs 9/20 0.32, ns 15/20 vs 3/20 <0.01, s
UFS vs RPL 21.05 ± 8.78 vs 
19.20 ± 6.14
0.44, ns 6.70 ± 4.50 vs 6.10 
± 2.81
0.007, s 648 ± 162 vs 
608 ± 154
0.42, ns 5/20 vs 3/20 0.69, ns 15/20 vs 17/20 0.69, ns
RPL vs CG 19.20 ± 6.14 vs 
7.85 ± 3.31
<0.01, s 6.10 ± 2.81 vs 
20.10 ± 9.44
<0.01, s 608 ± 154 vs 
vs 664 ± 175
0.20, ns 3/20 vs 9/20 0.08, ns 17/20 vs 3/20 <0.01, s
Hcy: homocysteine
MTHFR: methylenetetrahydrofolate reductase
UFS: unexplained female sterility group
RPL: recurrent pregnancy loss group
CG: control group
ns: not significant
s: significant
Table 1: Data of homocysteine metabolism in patients with sterility or RPL and in control subjects
Test (unit of measurement) UFS (subjects 20) RPL (subjects 20) CG (subjects 20)
Hcy (μM/ml) 21.05 ± 8.78 19.20 ± 6.14 7.85 ± 3.31
Serum folic acid (ng/ml) 6.70 ± 4.50 6.10 ± 2.81 20.10 ± 9.44
Serum vitamin B 12 (pg/ml) 648 ± 162 608 ± 154 664 ± 175
MTHFR C677T heterozigosity 5/20 3/20 9/20
MTHFR C677T homozigosity 15/20 17/20 3/20
Hcy: homocysteine
MTHFR: methylenetetrahydrofolate reductase
UFS: unexplained female sterility group
RPL: recurrent pregnancy loss group
CG: control groupThrombosis Journal 2007, 5:10 http://www.thrombosisjournal.com/content/5/1/10
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women with RPL but also in women with UFS (Table 1).
TT genotype of MTHFR C677T gene polymorphism has
been already underlined in pathophysiology of RPL by
several Authors but its role in pathophysiology of UFS is
still a matter of discussion. Therefore, our data support the
hypothesis concerning the involvement of homocysteine
metabolism in cases of UFS because frequency of TT gen-
otype was similar to that observed in women with RPL
(Table 2). Moreover, our data may also support previous
observations of an increased frequency of thrombophilia
in women with infertility showing repeated IVF failures.
Serum folate and vitamin B12 levels were also tested to
support this hypothesis because strongly associated to
homocysteine metabolism, also in terms of a possible
therapeutic support. Although, vitamin B12 levels were
lower both in women with RPL and with UFS compared
to control subjects, and these differences did not reach sta-
tistical significance (Table 1 and 2). On the other hand we
found significantly lower folate levels both in women
with RPL and UFS when compared with control subjects
(Table 1 and 2). These data confirm the strict association
between folate metabolism and homocysteine levels also
in pathophysiology of women with infertility, in particu-
lar if referred to adverse pregnancy outcome such as early
RPL. Moreover, for the first time we underlined a possible
association between low serum folate and HHCY and
UFS. Furthermore, from another point of view our data
offer a new scenario on the possible therapeutic support
with folic acid fortification both in women with RPL and
UFS carrying HHCY.
In conclusion our study provides several data concerning
the involvement of homocysteine metabolism in women
with infertility: we confirmed a strict association between
HHCY and TT genotype of MTHFR C677T in women with
RPL without other causes of recurrent abortion. Yet, for
the first time, we suggested also that homocysteine metab-
olism may be involved in pathophysiology of these cases
of UFS because of the association between HHCY, low
serum folate and TT genotype of MTHFR C677T. How-
ever, because of the small number of selected patients, our
data should be confirmed by further studies based on
larger population.
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